<DOC>
	<DOCNO>NCT00642616</DOCNO>
	<brief_summary>Examine effect TI combination anti-diabetic regimen include inhaled insulin versus anti-diabetic treatment without inhaled insulin lung function &amp; pulmonary safety</brief_summary>
	<brief_title>Evaluate Safety Technosphere® Insulin ( TI ) Diabetic Subjects With Moderate Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Asthma Physician diagnosis asthma history follow : recurrent wheezing , recurrent chest tightness , recurrent difficulty breathing , cough , particularly bad nighttime Never smoke former smoker ( = 6 month since cessation ) ≥18 year age Prebronchodilator Forced Expiratory Volume 1sec ( FEV1 ) ≥ 60 % Third National Health Nutrition Examination Survey ( NHANES III ) predict , prebronchodilator total lung capacity ( TLC ) ≥ 80 % predict Intermountain Thoracic Society ( ITS ) , prebronchodilator single breath carbon monoxide diffuse capacity lung ( DLco ) ( unc ) ≥70 % predict ( Miller ) &lt; 30 % daytoday variability daily morning Peak expiratory Volume ( PEF ) 2week runin period Significant improvement pre postbronchodilator spirometry ( defined increase baseline ≥ 12 % ≥ 200 mL FEV1 Forced Vital Capacity [ FVC ] ) Screening/Visit 1 document significant improvement pre postbronchodilator spirometry ( define ) within past 12 month subject 's medical record document positive methacholine challenge test within past 12 month COPD Physician diagnosis COPD ( include emphysema and/or chronic bronchitis ) , history dyspnea and/or intermittent daily chronic cough without sputum production , attributable know cause Former smoker ( ≥ 6 month since cessation ) smoke history ≥ 10 pack year ≥40 year age Postbronchodilator FEV1/FVC ratio &lt; 70 % Postbronchodilator FEV1 ≥ 50 % NHANES III predict , total lung capacity ( TLC ) ≥ 80 % predict ITS , DLco ( unc ) ≥ 50 % predict ( Miller ) Both Clinical diagnosis Type1 2 diabetes mellitus ≥ 12 month change antidiabetic regiment least 90days prior screen BMI , &lt; 39 kg/m2 Urine cotinine level ≤ 100ng/dL Clinical diagnosis obstructive lung disease HbA1C &gt; 6.5 % ≤ 11.5 % History pulmonary exacerbation within 8 week screening/V1 V1 V2 Use systemic corticosteroid antibiotic respiratory illness within 8 week screening/V1 OR V1 V2 Increase baseline use shortacting bronchodilator shortacting anticholinergic agent , combination 2 , ≥6 puff ≥3 nebulizer treatment per day ≥ 2 day Treatment supplemental oxygen therapy , room air oxygen saturation , 94 % history intubation ICU admission respiratory illness past 5 yr . Greater 2 hospitalization ER urgent care visit require &gt; 3 course systemic steroid past 12 month respiratory illness Use Symlin® ( pramlintide acetate ) within precede 90 day Two severe hypoglycemic episode within 6 month screen episode severe hypoglycemia Screening Baseline Previous exposure inhale insulin product Currently use insulin delivery pump Requires significant change ( define initiation new medication change dose frequency controller medication ) asthma COPD therapeutic regimen within 8 week Screening/Visit 1 ( Week 4 ) Visit 1 Baseline/Visit 2 Severe complication diabetes mellitus , opinion PI subinvestigator , include symptomatic autonomic neuropathy ; disable peripheral neuropathy ; active proliferative retinopathy ; nephropathy renal failure , renal transplant and/or dialysis ; history foot ulcer ; nontraumatic amputation due gangrene ; and/or vascular claudication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>